# Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

> **NCT00441701** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 99 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Navarixin 1 mg
- **DRUG:** Navarixin 10 mg
- **DRUG:** Placebo to match navarixin
- **DRUG:** Rescue medication

## Key facts

- **NCT ID:** NCT00441701
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12-01
- **Primary completion:** 2008-10-01
- **Final completion:** 2008-10-01
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2019-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441701, "Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00441701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*